Disclosures for "Safety and Efficacy of Cenobamate for the Treatment of Focal Seizures in Older Patients")
-
Dr. O'Dwyer has nothing to disclose.
-
Mr. Stern has received personal compensation for serving as an employee of Sk life science.
-
Mr. Wade has nothing to disclose.
-
Dr. Guggilam has received personal compensation for serving as an employee of SK Life Science, Inc.
-
The institution of Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arvelle Therapeutics. The institution of Dr. Rosenfeld has received personal compensation in the range of $500,000-$999,999 for serving as a Consultant for SK Life Science. Dr. Rosenfeld has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for SK Life Science. The institution of Dr. Rosenfeld has received research support from SK Life Science. The institution of Dr. Rosenfeld has received research support from UCB Pharma.